Merck's Vioxx Scandal: Ethics, Safety, and FDA Oversight
This paper analyzes the ethical dimensions of Merck Pharmaceuticals' handling of Vioxx (rofecoxib), a non-steroidal anti-inflammatory drug withdrawn from the market in 2004 after evidence linked it to significantly elevated risks of heart attack and stroke. The paper examines the VIGOR clinical study, allegations that Merck suppressed cardiovascular risk data from a New England Journal of Medicine publication, and the company's conflict of interest in sponsoring its own safety research. It also evaluates the ethics of direct-to-consumer pharmaceutical advertising and critiques the FDA's approval process for allowing post-market rather than pre-market safety research. The paper concludes that while Merck's eventual withdrawal of Vioxx was appropriate, it came far too late to prevent tens of thousands of preventable cardiac events.
- Introduction to Vioxx and Its Market History: Vioxx's development, FDA approval, and 2004 withdrawal
- The VIGOR Study and Cardiovascular Risk Evidence: VIGOR findings linking Vioxx to heart attack risk
- Data Suppression and the NEJM Publication: Missing cardiac data in the NEJM journal article
- Conflict of Interest in Pharmaceutical Research: Merck's role in sponsoring its own safety research
- Direct-to-Consumer Advertising and Its Ethical Implications: Ethics of marketing prescription drugs to consumers
- FDA Oversight Failures and Merck's Delayed Withdrawal: FDA approval gaps and the belated market withdrawal
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper maintains a clear ethical lens throughout, consistently distinguishing between what was legal and what was ethically defensible — a useful analytical habit in applied ethics writing.
- It uses a specific, well-documented case to build a multi-part argument, addressing research integrity, corporate disclosure obligations, advertising ethics, and regulatory failure in sequence.
- The concluding line — "the correct thing to do, it was just done 100,000 heart attacks too late" — is rhetorically effective, grounding abstract ethical claims in concrete human cost.
Key academic technique demonstrated
The paper demonstrates conflict-of-interest analysis in applied ethics: it identifies how Merck's financial stake in Vioxx's commercial success compromised the objectivity of both its internal research and the resulting publication, then connects this structural conflict to real patient harm. This technique — tracing how institutional incentives distort information — is central to pharmaceutical and business ethics writing.
Structure breakdown
The paper opens with background on Vioxx's development and FDA approval, then moves chronologically through the VIGOR study findings, the omission of data from the NEJM article, and internal corporate knowledge of risk. It pivots to two broader ethical questions — direct-to-consumer advertising and FDA pre-approval standards — before closing with a verdict on Merck's conduct. This case-to-principle structure is effective for applied ethics essays.
Introduction to Vioxx and Its Market History
Rofecoxib, marketed under the brand name Vioxx, is a non-steroidal anti-inflammatory drug (NSAID) developed by Merck Pharmaceuticals as a treatment for osteoarthritis, acute pain conditions, and dysmenorrhea. The drug received FDA approval in 1999 and was subsequently brought to market. However, in 2004, Merck voluntarily withdrew Vioxx from the market due to evidence that the drug significantly increased patients' risk of heart attack and stroke.
Create your account
Always verify citation format against your institution’s current style guide requirements.